189 related articles for article (PubMed ID: 32777106)
1. The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations.
Jondreville L; Krzisch D; Chapiro E; Nguyen-Khac F
Am J Hematol; 2020 Nov; 95(11):1361-1367. PubMed ID: 32777106
[TBL] [Abstract][Full Text] [Related]
2. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
4. Complex karyotype as a predictor of high-risk chronic lymphocytic leukemia: A single center experience over 12 years.
Kruzova L; Schneiderova P; Holzerova M; Vatolikova M; Divoka M; Turcsanyi P; Urbanova R; Kudelka M; Radvansky M; Kriegova E; Papajik T; Urbankova H
Leuk Res; 2019 Oct; 85():106218. PubMed ID: 31476701
[TBL] [Abstract][Full Text] [Related]
5.
Campo E; Cymbalista F; Ghia P; Jäger U; Pospisilova S; Rosenquist R; Schuh A; Stilgenbauer S
Haematologica; 2018 Dec; 103(12):1956-1968. PubMed ID: 30442727
[TBL] [Abstract][Full Text] [Related]
6. Prognostication of chronic lymphocytic leukemia in the era of new agents.
Eichhorst B; Hallek M
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):149-155. PubMed ID: 27913474
[TBL] [Abstract][Full Text] [Related]
7. The importance of complex karyotype in prognostication and treatment of chronic lymphocytic leukemia (CLL): a comprehensive review of the literature.
Jarošová M; Plevová K; Kotašková J; Doubek M; Pospíšilová Š
Leuk Lymphoma; 2019 Oct; 60(10):2348-2355. PubMed ID: 30773964
[TBL] [Abstract][Full Text] [Related]
8. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.
Yuan YY; Zhu HY; Wu JZ; Xia Y; Liang JH; Wu W; Cao L; Wang L; Fan L; Li JY; Xu W
Genes Chromosomes Cancer; 2019 Jan; 58(1):43-51. PubMed ID: 30350431
[TBL] [Abstract][Full Text] [Related]
9. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.
Blanco G; Puiggros A; Baliakas P; Athanasiadou A; García-Malo M; Collado R; Xochelli A; Rodríguez-Rivera M; Ortega M; Calasanz MJ; Luño E; Vargas M; Grau J; Martínez-Laperche C; Valiente A; Cervera J; Anagnostopoulos A; Gimeno E; Abella E; Stalika E; Hernández-Rivas JM; Ortuño FJ; Robles D; Ferrer A; Ivars D; González M; Bosch F; Abrisqueta P; Stamatopoulos K; Espinet B
Oncotarget; 2016 Dec; 7(49):80916-80924. PubMed ID: 27821812
[TBL] [Abstract][Full Text] [Related]
10. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine.
Van Den Neste E; Robin V; Francart J; Hagemeijer A; Stul M; Vandenberghe P; Delannoy A; Sonet A; Deneys V; Costantini S; Ferrant A; Robert A; Michaux L
Leukemia; 2007 Aug; 21(8):1715-22. PubMed ID: 17541398
[TBL] [Abstract][Full Text] [Related]
11. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption.
Garces S; Khoury JD; Kanagal-Shamanna R; Salem A; Wang SA; Ok CY; Hu S; Patel KP; Routbort MJ; Luthra R; Tang G; Schlette EJ; Bueso-Ramos CE; Medeiros LJ; Loghavi S
Hum Pathol; 2018 Dec; 82():215-231. PubMed ID: 30086334
[TBL] [Abstract][Full Text] [Related]
12. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.
Pospisilova S; Gonzalez D; Malcikova J; Trbusek M; Rossi D; Kater AP; Cymbalista F; Eichhorst B; Hallek M; Döhner H; Hillmen P; van Oers M; Gribben J; Ghia P; Montserrat E; Stilgenbauer S; Zenz T;
Leukemia; 2012 Jul; 26(7):1458-61. PubMed ID: 22297721
[TBL] [Abstract][Full Text] [Related]
13. What is the best frontline therapy for patients with CLL and 17p deletion?
Badoux XC; Keating MJ; Wierda WG
Curr Hematol Malig Rep; 2011 Mar; 6(1):36-46. PubMed ID: 21153774
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Montserrat E; Dreger P
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13).
Dong HJ; Zhou LT; Zhu DX; Wang DM; Fang C; Zhu HY; Zhuang Y; Miao KR; Xu W; Li JY
Ann Hematol; 2011 Jun; 90(6):709-17. PubMed ID: 21113594
[TBL] [Abstract][Full Text] [Related]
18. Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
Do C; Best OG; Thurgood L; Hotinski A; Apostolou S; Mulligan SP; Lower K; Kuss B
Br J Haematol; 2021 May; 193(3):556-560. PubMed ID: 33851417
[TBL] [Abstract][Full Text] [Related]
19. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.
Baliakas P; Jeromin S; Iskas M; Puiggros A; Plevova K; Nguyen-Khac F; Davis Z; Rigolin GM; Visentin A; Xochelli A; Delgado J; Baran-Marszak F; Stalika E; Abrisqueta P; Durechova K; Papaioannou G; Eclache V; Dimou M; Iliakis T; Collado R; Doubek M; Calasanz MJ; Ruiz-Xiville N; Moreno C; Jarosova M; Leeksma AC; Panayiotidis P; Podgornik H; Cymbalista F; Anagnostopoulos A; Trentin L; Stavroyianni N; Davi F; Ghia P; Kater AP; Cuneo A; Pospisilova S; Espinet B; Athanasiadou A; Oscier D; Haferlach C; Stamatopoulos K;
Blood; 2019 Mar; 133(11):1205-1216. PubMed ID: 30602617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
